Author: Xudan Chen; Yang Zhang; Baoyi Zhu; Jianwen Zeng; Wenxin Hong; Xi He; Jingfeng Chen; Haipeng Zheng; Shuang Qiu; Ying Deng; Juliana Chan; Jian Wang
Title: Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study Document date: 2020_4_14
ID: 9j4ese89_28
Snippet: In this study, the median time from illness onset to viral RNA clearance was 12 days. This was compared to 15 days reported in patients from Wuhan [18] , which might reflect the more severe nature of the latter patients. Currently, there is no consensus on the de-isolation management for patients with COVID-19, especially in asymptomatic subjects with high risk of infectivity. In this cohort, 89% of patients achieved viral RNA clearance within 21.....
Document: In this study, the median time from illness onset to viral RNA clearance was 12 days. This was compared to 15 days reported in patients from Wuhan [18] , which might reflect the more severe nature of the latter patients. Currently, there is no consensus on the de-isolation management for patients with COVID-19, especially in asymptomatic subjects with high risk of infectivity. In this cohort, 89% of patients achieved viral RNA clearance within 21 days, and only 66% within 14 days. Specifically, all asymptomatic patients achieved viral RNA clearance within 21 days. These data suggested that isolation for at least 21 days after the onset of symptom or first positive PCR test is warranted in both patients without or with improving symptoms. . This drug is being recommended for the treatment of hospitalized COVID-19 patients in China and some countries [11, 17] . In this study, 28 patients were treated with chloroquine which did not appear to improve viral RNA clearance compared to supportive treatment. Large scale randomized controlled studies are needed to confirm its benefit, if any.
Search related documents:
Co phrase search for related documents- asymptomatic patient and control study: 1
- asymptomatic patient and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- asymptomatic patient and infectivity high risk: 1
- asymptomatic patient and large scale: 1, 2, 3
- asymptomatic patient and median time: 1, 2, 3
- asymptomatic subject and high risk: 1, 2
- benefit confirm and control study: 1
- benefit confirm and high risk: 1
- benefit confirm and median time: 1
- China patient and high risk: 1, 2, 3, 4, 5
- China patient and large scale: 1
- China patient and median time: 1
- control study and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control study and large scale: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control study and median time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- de isolation and large scale: 1
- de isolation and median time: 1
- high risk and large scale: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- high risk and median time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date